| 287.84 6.42 (2.28%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 365.4  |
1-year : | 426.79 |
| Resists | First : | 312.85 |
Second : | 365.4 |
| Pivot price | 289.35 |
|||
| Supports | First : | 280.55 |
Second : | 260.58 |
| MAs | MA(5) : | 295.8  |
MA(20) : | 285.65 |
| MA(100) : | 292.53 |
MA(250) : | 280.74 |
|
| MACD | MACD : | 5 |
Signal : | 4.8 |
| %K %D | K(14,3) : | 46.2 |
D(3) : | 63.4 |
| RSI | RSI(14): 51.7 |
|||
| 52-week | High : | 343.11 | Low : | 211.42 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BIO ] has closed above bottom band by 46.0%. Bollinger Bands are 17.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 288.63 - 290.06 | 290.06 - 291.5 |
| Low: | 277.14 - 278.61 | 278.61 - 280.1 |
| Close: | 285.45 - 287.81 | 287.81 - 290.19 |
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Mon, 27 Apr 2026
Assessing Bio-Rad Laboratories (BIO) Valuation After Citi Downgrade And China Diagnostics Concerns - simplywall.st
Fri, 24 Apr 2026
Bio-Rad Laboratories Stockholders Approve Directors and Governance Items - TipRanks
Fri, 24 Apr 2026
Shareholders of Bio-Rad (NYSE: BIO) approve 2017 incentive plan changes - Stock Titan
Fri, 24 Apr 2026
Bio-Rad Laboratories, Inc. (BIO) PT Reduced to $300 by Citigroup Amid Process Chromatography Concerns - Yahoo Finance
Thu, 23 Apr 2026
Bio-Rad Laboratories Inc (BIO) Shares Fall 6.4% -- What GF Score of 77 Tells Investors - GuruFocus
Thu, 23 Apr 2026
Bio-Rad (NYSE: BIO) director exercises 407 RSUs and receives 369-unit grant - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 22 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 16.2 (%) |
| Held by Institutions | 90.8 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 947 (K) |
| EPS | 27.84 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 276.16 |
| Profit Margin | 29.4 % |
| Operating Margin | 8.8 % |
| Return on Assets (ttm) | 1.6 % |
| Return on Equity (ttm) | 10.8 % |
| Qtrly Rev. Growth | 3.9 % |
| Gross Profit (p.s.) | 61.13 |
| Sales Per Share | 117.7 |
| EBITDA (p.s.) | 19.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 532 (M) |
| Levered Free Cash Flow | 257 (M) |
| PE Ratio | 10.33 |
| PEG Ratio | 4 |
| Price to Book value | 1.04 |
| Price to Sales | 2.44 |
| Price to Cash Flow | 11.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|